HER2-POSITIVE BREAST CANCER

This study is testing whether giving two cancer drugs—docetaxel (chemotherapy) and trastuzumab (a targeted therapy)—before surgery can help eliminate tumors in Nigerian women with HER2-positive breast cancer. The trial involves 53 women with stage II or III breast cancer who have…

This study is testing whether some patients with early-stage, HER2-positive breast cancer can safely avoid chemotherapy before surgery. Researchers are using a special scan and specific tumor markers to identify patients whose cancer is highly dependent on the HER2 protein. These…

This study is testing a new, potentially less toxic chemotherapy combination for people with early-stage HER2-positive breast cancer. Researchers want to see if this gentler treatment works as well as the standard, stronger chemotherapy at eliminating cancer before surgery. The s…

This early-phase study is testing a personalized vaccine for people with HER2-positive breast cancer. The vaccine is made from the patient's own immune cells and is designed to teach the body's immune system to attack the cancer. Researchers are giving the vaccine alongside stand…

This study is testing whether a new drug called DB-1303 works better and is as safe as the current treatment, T-DM1, for people with advanced HER2-positive breast cancer that has spread or cannot be removed by surgery. The trial will involve about 224 adults whose cancer has prog…

This study is testing whether adding the pill tucatinib to two standard injected drugs (trastuzumab and pertuzumab) works better to control advanced HER2-positive breast cancer that has spread. It involves 654 people whose cancer responded to initial treatment and is now in a 'ma…

This study aimed to see if using a shorter, gentler course of chemotherapy before surgery could effectively treat early-stage HER2-positive breast cancer. The plan was to give patients four cycles of chemo and targeted drugs before surgery, then adjust the follow-up treatment bas…

This study is testing whether adding a medication called pegfilgrastim to standard pre-surgery treatment improves outcomes for people with HER2-positive breast cancer. Pegfilgrastim helps boost white blood cell counts. Researchers want to see if this boost helps the main cancer d…

This study compares two different drug combinations given before surgery to shrink tumors in people with stage II-III HER2-positive breast cancer. About 174 participants were randomly assigned to receive either a newer drug combination (margetuximab) or the standard combination (…

This study is testing whether adding a new experimental drug, TVB-2640, to standard treatments can help control advanced HER2-positive breast cancer that has spread and is no longer responding to the usual therapies. It involves a small group of patients whose cancer has progress…

This study is testing if adding a pill called tucatinib to a standard breast cancer drug (T-DM1) works better to control advanced HER2-positive breast cancer. It is for people whose cancer has spread or cannot be removed by surgery and has worsened after prior treatment. About 46…

This study is testing whether patients with advanced HER2-positive breast cancer can safely stop their targeted treatment after having their cancer under control for at least three years. The trial involves 82 participants who will either continue treatment or stop it, with resea…

This early-stage study is testing the safety and best dose of a new drug, ELVN-002, when given with standard treatments for advanced HER2-positive cancers. It will involve about 275 adults with cancers like breast, colorectal, or gastric cancer that have spread or returned after …

This early-stage study is testing a new oral medication called ZN-A-1041 for people with advanced HER2-positive cancers that have spread or returned after treatment. Researchers will give the drug alone or combined with other standard cancer therapies to about 210 participants to…

This study aimed to test whether a combination PET/MRI scan could detect how well treatment is working in stage IV HER2-positive breast cancer patients earlier than current methods. Researchers planned to scan patients up to three times during their treatment to see if changes in…

This study tests whether two common heart medications can prevent heart damage in breast cancer patients receiving targeted therapy. Researchers want to see if giving carvedilol (a beta blocker) and/or empagliflozin (an SGLT2 inhibitor) alongside cancer treatment is safe and feas…

This study is testing two different vaccines designed to prevent breast cancer from returning in patients with HER2-positive disease. It focuses on people who still had cancer cells remaining after completing their initial chemotherapy and targeted therapy. Researchers will monit…

This study aims to see if MRI scans taken before and after standard breast cancer treatment can predict how well the immune system is fighting the cancer. Researchers will compare MRI images with tissue samples from 13 patients with HER2-positive breast cancer. This is an observa…

This study aims to understand how a special exercise test can help predict heart and lung function in women with HER2-positive breast cancer who are experiencing mild heart side effects from their treatment. Researchers will measure oxygen use during exercise in 23 participants w…

This study aims to understand how the environment immediately surrounding a HER2-positive breast tumor changes when a patient receives chemotherapy before surgery. Researchers will observe 30 patients undergoing this standard treatment to see how the tumor's local area responds. …

This small study is testing a new type of PET scan to see if it can predict which patients with advanced HER2-positive breast cancer will benefit from a specific drug treatment. Researchers attach a tiny radioactive tag to a cancer drug and use a scanner to see where it goes in t…